Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CSNK1A1L | Q8N752 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7461587 | 0.82 | CA2 (0.52) | — | |
| SCHEMBL14419778 | 0.82 | LMNA (0.41) | ENPP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL7806579 | 0.82 | — | — | |
| SCHEMBL12157467 | 0.80 | GRK6 (0.47) | SCDALOX5 | |
| SCHEMBL2028396 | 0.80 | ADH5 (0.32) | — | |
| SCHEMBL14194264 | 0.79 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL13411813 | 0.78 | ADH5 (0.36) | — | |
| SCHEMBL22497118 | 0.77 | SLC9A1 (0.42) | SCDALDH1A1SMN1; SMN2 | |
| SCHEMBL8824901 | 0.76 | PFKFB3 (0.30) | — | |
| SCHEMBL8824902 | 0.76 | PFKFB3 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855725-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040063749-A1 | Excitatory amino acid receptor antagonists | BLEISCH THOMAS JOHN (US) | 2004-04-01 | — | — | US | disclosed |
| EP-1351952-A2 | PYRROLIDINYLMETHYL SUBSTITUTED DECAHYDROISOQUINOLINES AS EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002053556-A2 | PYRROLIDINYLMETHYL SUBSTITUTED DECAHYDROISOQUINOLINES AS EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063749-A1 | Excitatory amino acid receptor antagonists | SLC1A2, SLC1A1, SLC1A3 | PTGS2 670/4885WNT3A 4150/4885TNKS2 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.